Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07482176 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

A Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD, sponsored by Adverum Biotechnologies.

Recruiting
Registry status
Phase 3
Development phase
284
Enrollment target
2
Study locations

NCT07482176 is a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD that is actively recruiting participants, run by Adverum Biotechnologies. The registered enrollment target is 284 participants, above the 177-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (60% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07482176, a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) and Wet AMD, is actively recruiting participants, sponsored by Adverum Biotechnologies.

RECRUITING
Registry status
Phase 3
Development phase
284 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to intravitreal aflibercept (active comparator). The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured as an average at Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.

Conditions Studied

Neovascular Age-related Macular Degeneration (nAMD) Wet AMD

Interventions

  • GENETIC Ixo-vec
  • DRUG Aflibercept

Study Locations (2)

Texas

  • Adverum Clinical Site 231 - The Woodlands

Virginia

  • Adverum Clinical Site 199 - Lynchburg

Trial Details

FieldValue
Enrollment Target 284 participants
Start Date 2026-03-16
Est. Completion 2031-10-20
Phase Phase 3

Sponsor

Adverum Biotechnologies

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07482176

The ClinicalTrials.gov registry entry for NCT07482176 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (60% higher). The listed sponsor is Adverum Biotechnologies, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 2 interventions - of which Ixo-vec is the first listed.

NCT07482176 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.

Frequently Asked Questions

What is clinical trial NCT07482176 about?

NCT07482176 is a clinical study titled "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)". This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection o...

What is the current status of trial NCT07482176?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2026-03-16. Estimated completion is 2031-10-20.

What conditions does trial NCT07482176 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD), Wet AMD.

What interventions are being tested in trial NCT07482176?

The interventions under investigation include: Ixo-vec (GENETIC), Aflibercept (DRUG).

Who is sponsoring clinical trial NCT07482176?

This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07482176 being conducted?

This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration (nAMD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neovascular Age-related Macular Degeneration (nAMD)

All registered trials for this condition

Wet AMD

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.